Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials
JAMA Intern Med
.
2019 May 1;179(5):721-722.
doi: 10.1001/jamainternmed.2018.8019.
Authors
Joseph S Ross
1
2
,
Christina C Wee
2
3
Affiliations
1
Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
2
Associate Editor.
3
Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
PMID:
30830205
DOI:
10.1001/jamainternmed.2018.8019
No abstract available
Publication types
Comment
MeSH terms
Cohort Studies
Communication*
Research Design*